SOURCE: Consilient Health

November 22, 2005 04:00 ET

Consilient Health Ltd. Concludes Licensing/Supply Agreement With Bentley Pharmaceuticals Inc.

DUBLIN, IRELAND -- (MARKET WIRE) -- November 22, 2005 -- Consilient Health Ltd., an Irish-based, pan-European generic pharmaceutical company announced today that it has entered into a non-exclusive agreement with Bentley Pharmaceuticals, Inc., to distribute and market omeprazole, the generic proton pump inhibitor, used in the treatment of acid-related gastrointestinal disorders, which will be manufactured by Bentley's subsidiary, Laboratorios Belmac, S.A. Bentley Pharmaceuticals Ireland Limited has recently established a subsidiary in Ireland and received approval from the Irish Medicines Board to market 10 mg., 20 mg., and 40 mg. capsules of generic omeprazole in Ireland.

Douglas B. Andrews, Consilient Health's Founder and CEO, observed that this agreement marked another milestone in the expansion of the Company's product portfolio in the British market. Since July of this year, Consilient Health has introduced both lamotrigine and terbinafine, whose core patents expired earlier this year, in the United Kingdom. The Company is also active in the Dutch and Scandinavian generic pharmaceutical markets.

James R. Murphy, Bentley's Chairman and CEO, also commented: "We believe that Consilient's expertise in the distribution of high-quality generic pharmaceuticals will help to expedite the European growth of our generic omeprazole product. Our agreement reaffirms our strategy to continue to team with other established organizations as essential building block for our growth."

About Consilient Health, Ltd.

Consilient Health, Ltd. markets and distributes generic pharmaceuticals utilizing a large network of manufacturers and business partners. Consilient Health is a reliable, committed and trustworthy generic pharmaceutical company that strives to make healthcare affordable across Europe. Consilient's decades of managerial experience in the drug and healthcare industries coupled with an innovative business model results in significant cost savings, which in turn are shared with business partners and patients. Consilient Health wants to help improve the way generic drugs are distributed and marketed throughout Europe. Additional information about Consilient Health may be obtained through their web site at

About Bentley Pharmaceuticals, Inc.

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company, based in Exeter, N.H. (U.S.A.) and focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiary, Laboratorios Belmac, and markets these pharmaceutical products through its subsidiaries, Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar and Bentley Pharmaceuticals Ireland; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API. Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at

Contact Information